ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight
Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.
You may also be interested in...
Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience
T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.
ASH First Look: CAR-T Therapies Against BCMA, CD19 And More
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.